1
Ian S Mitchell, James F Blake, Rui Xu, Nicholas C Kallan, Dengming Xiao, Keith Lee Spencer, Josef R Bencsik, Eli M Wallace, Stephen T Schlachter, Anna L Banka, Jun Liang, Brian Safina, Birong Zhang, Christine Chabot, Steven Do: Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors. Array BioPharma, Covenentech, Viksnins Harris & Padys PLLP, November 22, 2011: US08063050 (25 worldwide citation)

The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatmen ...


2
Ian S Mitchell, James F Blake, Rui Xu, Nicholas C Kallan, Dengming Xiao, Keith Lee Spencer, Josef R Bencsik, Eli M Wallace, Stephen T Schlachter, Anna L Banka, Jun Liang, Brian Safina, Jun Li, Christine Chabot: Pyrimidyl cyclopentanes as AKT protein kinase inhibitors. Array BioPharma, Genertech, Viksnins Harris & Padys PLLP, August 23, 2011: US08003651 (22 worldwide citation)

The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for ...


3
Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Daniel Ortwine, Brian Safina, Shaoyi Sun, Daniel P Sutherlin, Alla Yurevna Zenova: N-substituted benzamides and methods of use thereof. Xenon Pharmaceuticals, Genentech, Viksnins Harris & Padys PLLP, January 13, 2015: US08933236 (10 worldwide citation)

The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and m ...


4
Ian S Mitchell, James F Blake, Rui Xu, Nicholas C Kallan, Dengming Xiao, Keith Lee Spencer, Josef R Bencsik, Eli M Wallace, Stephen T Schlachter, Anna L Banka, Jun Liang, Brian Safina, Birong Zhang, Christine Chabot, Steven Do: Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors. Array Biopharma, Genentech, Viksnins Harris & Padys PLLP, October 7, 2014: US08853199 (7 worldwide citation)

The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatmen ...


5
Ian S Mitchell, James F Blake, Rui Xu, Nicholas C Kallan, Dengming Xiao, Keith Lee Spencer, Josef R Bencsik, Eli M Wallace, Stephen T Schlachter, Anna L Banka, Jun Liang, Brian Safina, Jun Li, Christine Chabot: Pyrimidyl cyclopentanes as AKT protein kinase inhibitors. Array BioPharma, Genentech, Viksnins Harris & Padys PLLP, September 30, 2014: US08846681 (7 worldwide citation)

The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for ...


6
Jean Christophe Andrez, Sultan Chowdhury, Shannon Marie Decker, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Qi Jia, Jun Li, Daniel F Ortwine, Brian Safina, Tao Sheng, Shaoyi Sun, Daniel P Sutherlin, Michael Scott Wilson, Alla Yurevna Zenova: N-substituted benzamides and methods of use thereof. Xenon Pharmaceuticals, Genentech, Viksnins Harris & Padys PLLP, February 10, 2015: US08952169 (7 worldwide citation)

The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and m ...


7
Georgette Castanedo, Bryan Chan, David Goldstein, Rama Kondru, Matthew Lucas, Wylie Palmer, Stephen Price, Brian Safina, Pascal Pierre Alexandre Savy, Eileen Mary Seward, Daniel P Sutherlin, Zachary K Sweeney: Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use. Genentech, Alex Andrus, May 8, 2012: US08173650 (3 worldwide citation)

Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, or (iv) X1 is CR7 and X2 is O, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, ...


8
Ian S Mitchell, James F Blake, Rui Xu, Nicholas C Kallan, Dengming Xiao, Keith Lee Spencer, Josef R Bencsik, Eli M Wallace, Stephen T Schlachter, Anna L Leivers, Jun Liang, Brian Safina, Birong Zhang, Christine Chabot, Steven Do: Hydroxylated and methoxylated pyrimidyl cyclopentanes as Akt protein kinase inhibitors. Array BioPharma, Genentech, Viksnins Harris & Padys PLLP, June 7, 2016: US09359340 (2 worldwide citation)

The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula I: Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatmen ...


9
Josef Bencsik, James F Blake, Nicholas C Kallan, Ian S Mitchell, Keith L Spencer, Dengming Xiao, Rui Xu, Christine Chabot, Steven Do, Jun Liang, Brian Safina, Birong Zhang, James Graham: Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor. Array BioPharma, Genentech, Viksnins Harris & Padys PLLP, October 7, 2014: US08853216 (2 worldwide citation)

The present invention provides a compound and pharmaceutically acceptable salts thereof, comprising the Formula I. Also provided are methods of using the compound of this invention as an AKT protein kinase inhibitor and for the treatment of hyperproliferative diseases such as cancer.


10
Josef R Bencsik, James F Blake, Nicholas C Kallan, Ian S Mitchell, Keith Lee Spencer, Dengming Xiao, Rui Xu, Christine Chabot, Steven Do, Jun Liang, Brian Safina, Birong Zhang: Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors. Array Biopharma, Genentech, Viksnins Harris & Padys PLLP, September 16, 2014: US08835434 (2 worldwide citation)

The present invention provides compounds, including pharmaceutically acceptable salts thereof, comprising the Formula (I): Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases, such as cancer.